Protection of curcumin against tumor necrotic factor-alpha-mediated inflammatory injury of vascular endothelial cells

Chinese Journal of Tissue Engineering Research

Volumn 18, Issue 38, 2014, Pages 6165-6171

  Zhao, Yun ^a,b   Han, Xiu Min ^a   Zhao, Ming ^a   Sun, Ying Hui ^a   Zhu, Xian Yang ^a   Zhang, Duan Zhen ^a  

^a GENERAL HOSPITAL OF NORTHERN THEATER COMMAND   (China)

^b DALIAN MEDICAL UNIVERSITY   (China)

Author keywords

Blood vessels; Endothelial cells; Nuclear factor B; Tumor necrosis factor alpha

Indexed keywords

ACTIN; CURCUMIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; INTERLEUKIN 1BETA CONVERTING ENZYME; PHALLOIDIN; RHODAMINE; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; BIOLOGICAL ACTIVITY; CELL MEMBRANE PERMEABILITY; CELL PROTECTION; CELL STRESS; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; INFLAMMATION; PROTEIN EXPRESSION; STRESS FIBER; VASCULAR ENDOTHELIUM;

EID: 84934776002     PISSN: 16738225     EISSN: None     Source Type: Journal    
DOI: 10.3969/j.issn.2095-4344.2014.38.017     Document Type: Article

References (28)

1. McLaughlin VV, Archer SL, Badesch DB, et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of cardiology foundation task force on expert consensus documents and the American Heart Association: developed in collaboration with the American College of Chest Physicians, American Thoracic Society, Inc., and the Pulmonary Hypertension Association. Circulation. 2009;119(16):2250-2294.
2. Price LC, Wort SJ, Perros F, et al. Inflammation in pulmonary arterial hypertension. Chest, 2012;141(1):210-221.
3. Schermuly RT, Ghofrani HA, Wilkins MR, et al. Mechanisms of disease: pulmonary arterial hypertension. Nat Rev Cardiol. 2011;8(8):443-455.
4. Rabinovitch M. Molecular pathogenesis of pulmonary arterial hypertension. J Clin Invest. 2008;118(7):2372-2379.
5. McLaughlin VV, Davis M, Cornwell W. Pulmonary arterial hypertension. Curr Probl Cardiol. 2011;36(12):461-517.
6. Simonneau G, Robbins IM, Beghetti M, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2009;54(Suppl. 1):S43-54.
7. Zhou H, Beevers CS, Huang S. The targets of curcumin. Curr Drug Targets. 2011;12(3):332-347.
8. Aggarwal BB, Sung B. Pharmacological basis for the role of curcumin in chronic diseases: an ageold spice with modern targets. Trends Pharmacol Sci. 2009;30:85-94.
9. Singh S. From exotic spice to modern drug? Cell. 2007;130: 765-768.
10. Huang MT, Newmark HL, Frenkel K. Inhibitory effects of curcumin on tumorigenesis in mice. J cell Biochem Suppl. 1997;27:26-34.
11. Motterlini R, Foresti R, Bassi R, et al. Curcumin, an antioxidant and anti-inflammatory agent, induces heme oxygenase-1and protects endothelial cells against oxidative stress. Free Radic Biol Med. 2000;28(8):1303-1312.
12. Bronte E, Coppola G, Di Miceli R, et al. Role of curcumin in idiopathic pulmonary arterial hypertension treatment: a new therapeutic possibility. Med Hypotheses. 2013;81(5): 923-926.
13. Essler M, Retzer M, Bauer M, et al. Mildly oxidized low density lipoprotein induces contraction of human endothelial cells through activation of Rho/Rho kinase and inhibition of myosin light chain phosphatase. J Biol Chem. 1999; 274(43): 30361-30364.
14. Wojciak-Stothard B, Potempa S, Eichholtz T, et al. Rho and Rac but not Cdc42 regulate endothelial cell permeability. J Cell Sci. 2001;114(7):1343-1355.
15. Murakami M, Simons M. Regulation of vascular integrity. J Mol Med. 2009; 87(6):571-582.
16. Bazzoni G. Endothelial tight junctions: permeable barriers of the vessel wall. Thromb Haemost. 2006;95(1):36-42.
17. Williams MR, Kataoka N, Sakurai Y, et al. Gene expression of endothelial cells due to interleukin-1 beta stimulation and neutrophil transmigration. Endothelium. 2008;15(1):73-165.
18. Tracey KJ, Cerami A. Tumor necrosis factor: a pleiotropic cytokine and therapeutic target. Annu Rev Med. 1994;45: 491-503.
19. Lévy M, Maurey C, Celermajer DS, et al. Impaired apoptosis of pulmonary endothelial cells is associated with intimal proliferation and irreversibility of pulmonary hypertension in congenital heart disease. Am Coll Cardiol. 2007;49(7): 803-810.
20. 22] Simonneau G, Gatzoulis MA, Adatia I, et al. Updated clinical classification of pulmonary ypertension. J Am Coll Cardiol. 2013;62(25 Suppl):D34-41.
21. Ortiz A, Lorz C, Catalán MP, et al. Expression of apoptosis regulatory proteins in tubular epithelium stressed in culture or following acute renal failure. Kidney Int. 2000;57(3): 969-981.
22. Mathew SJ, Haubert D, Krönke M, et al. Looking beyond death: a morphogenetic role for the TNF signalling pathway. J Cell Sci. 2009;122(Pt 12): 1939-1946.
23. Benza RL, Miller DP, Gomberg-Maitland M, et al. Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL). Circulation. 2010;122(2):164-172
24. Humbert M, Sitbon O, Chaouat A, et al. Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era. Circulation. 2010;122(2):156-163.
25. Aggarwal BB, Gupta SC, Sung B. Curcumin: an orally bioavailable blocker of TNF and other pro-inflammatory biomarkers. Br J Pharmacol. 2013;169(8):1672-1692.
26. Epstein J, Sanderson IR, Macdonald TT. Curcumin as a therapeutic agent: the evidence from in vitro, animal and human studies. Br J Nutr. 2010;103(11):1545-1557.
27. McGuire TR, Kazakoff PW, Hoie EB, et al. Antiproliferative activity of shark cartilage with and without tumor necrosis factor-alpha in human umbilical vein endothelium. Pharmacotherapy. 1996;16(2): 237-244.
28. Zhang H, Park Y, Wu J, et al. Role of TNF-alpha in vascular dysfunction. Clin Sci (Lond). 2009;116(3): 219-230.